An experimental tuberculosis (TB) vaccine developed by GlaxoSmithKline (GSK) protects half the people who received it, scientists announced at the 50th union world conference on lung health earlier this week, offering fresh hope in the fight against the deadly disease.

Finding new ways to combat TB is particularly important for SA, where the HIV epidemic has fuelled the spread of the infectious disease. In 2018, SA had 301,000 new TB cases, and the disease killed an estimated 63,000 people, according to the World Health Organisation. Millions more South Africans have dormant, or latent, TB...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now